| 2005-02-09: |
SEQUENOM and Iceland Genomics Announce Research Collaboration to Investigate Role of Cancer Predisposition Genes
San Diego, California and Reykjavik, Iceland ( PRN/ots ) - - Continues Research to Validate Significance of SEQUENOM's Portfolio of Breast Cancer Genetic Discoveries SEQUENOM, Inc. ( NASDAQ: SQNM ) and Iceland Genomics Corporation ( Iceland Genomics ), a privately - held company, entered into a research collaboration to analyze (...) |
| 2011-02-21: |
Nordion Signs Share Purchase Agreement to Divest MDS Nordion S.A.
Ottawa, Canada ( PRN/ots ) - Nordion Inc. , a leading provider of products and services to the global health science market, today announced it has signed a share purchase agreement ( SPA ) with Best Medical Belgium ( Best Medical ) for the divestiture of the Company's Belgian operations, (...) |
| 2006-09-08: |
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX( r ) ( Enoxaparin Sodium Injection ) Vs. Unfractionated Heparin ( UFH ) in Patients Undergoing Non - Emergent Percutaneous Coronary Intervention
Paris ( PRN/ots ) - The New England Journal of Medicine publishes the international STEEPLE trial ( Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention ( PCI ): An International Randomized Evaluation ), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated with significantly (...) |
| 2006-01-05: |
Isotechnika Enrols First Patient in Phase IIb Kidney Transplant Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company enrolled its first patient in a North American Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247, on January 4, 2006. The trial will be performed at thirty - four centers (...) |
| 2006-10-18: |
New Research Shows That Single Pill amlodipine besylate/atorvastatin calcium May Reduce 10 - Year Risk for a Heart Attack or Stroke by More Than 50 Percent
Fukuoka, Japan ( PRN/ots ) - - Therapy May Benefit Hypertensive Patients With Additional Risk Factors in Populations Across Asia and Latin America Single - pill amlodipine besylate/atorvastatin calcium ( Caduet( R ) ) may reduce the 10 - year risk of having a cardiovascular ( CV ) event - as determined (...) |
| 2007-06-19: |
Organon's Once - a - Month Contraceptive Ring, NuvaRing( R ) Completes European Authorization
Oss, The Netherlands ( PRN/ots ) - Organon announced today that NuvaRing( R ) ( etonogestrel/ethinyl estradiol vaginal ring ), the company's once - a - month contraceptive, has successfully completed the European Mutual Recognition Procedure ( MRP ) in an additional 13 countries ( 1 ). NuvaRing is already approved in 14 European Union (...) |
| 2009-09-30: |
Muscle and Joint Pain Costs European Economies up to EUR240 Billion a Year
Brussels ( PRN/ots ) - - New Study Reveals Musculoskeletal Disorders ( MSDS ) Responsible for More Sick Days Than any Other Health Condition A new study today finds that musculoskeletal disorders ( MSDs ) account for nearly half ( 49 Prozent ) of all absences from work and 60 Prozent of permanent (...) |
| 2008-11-27: |
Bacardi Limited Offers "Driving Experience of a Lifetime" With F1( TM ) Legend Michael Schumacher
Hamilton, Bermuda, November 27 ( PRN/ots ) - - Schumacher - The Ultimate Designated Driver - Promotes Drinking and Driving Don't Mix at http://www.championsdrinkresponsibly.com Bacardi Limited, as part of its responsible drinking "Champions Drink Responsibly" campaign, is providing the drive of a lifetime - the opportunity (...) |
| 2008-08-26: |
After Their U.S. Purchase, Algorithme Pharma Gains a Foothold in Europe Through the Acquisition of a New Clinical Research Location in the United Kingdom
Laval, Canada ( PRN/ots ) - The Laval - based firm Algorithme Pharma is pleased to announce that it has achieved its goal of securing a European facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only six weeks after confirming (...) |
| 2007-09-18: |
Actonel Halves Risk of Fracture in Osteoporotic Women With History of Hip Fracture
Honolulu, Hawaii ( PRN/ots ) - New data show that Actonel( R ) 5mg ( risedronate sodium tablets ) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with osteoporosis who have suffered a previous hip fracture( 1 ) - a group of patients at (...) |
| 2009-03-20: |
Another LNA - based RNA Inhibitor Enters Clinical Trials
Copenhagen ( PRN/ots ) - - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients With Solid Tumors and Lymphomas Santaris Pharma announced today that the fourth LNA - based drug has been brought into the clinic. (...) |
| 2005-10-31: |
Innovative Drug Tarceva Now Available in Europe to Tackle Growing Lung Cancer Epidemic
Basel, Switzerland ( PRN/ots ) - The news that the innovative new cancer drug Tarceva( R ) ( erlotinib ) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have (...) |
| 2010-11-08: |
Study Shows Cardiovascular Deaths in Europe Could Be Prevented
Prague, November 8 ( PRN/ots ) - Cardiovascular disease ( CVD ) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan - European study announced today indicate that many of these deaths could be avoided if (...) |
| 2008-03-31: |
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Indianapolis ( PRN/ots ) - - Late - stage IDENTITY study of once - daily, oral agent is now enrolling patients Eli Lilly and Company ( NYSE: LLY ) has announced today the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the (...) |
| 2008-11-12: |
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
Paris, November 12 ( PRN/ots ) - - Sanofi Pasteur and Chumakov Institute Russian Academy Medical Sciences Providers of Inactivated Polio Vaccine ( IPV ) IMOVAX PolioTM for Russia National "Project Health" Sanofi Pasteur, the vaccines division of sanofi - aventis Group, announced today that Russia has chosen (...) |
| 2010-03-09: |
The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
Seoul, March 9, 2010 ( PRN/ots ) - PDVI ( Pediatric Dengue Vaccine Initiative ), a program of the International Vaccine Institute ( IVI ) funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide. Breaking (...) |
| 2010-06-08: |
Football Stars Unite to Tackle Back Pain
Rome, June 8, 2010 ( PRN/ots ) - UK Premiership footballer Rory Delap, renowned for his devastating throw - in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young men and women (...) |
| 2011-04-04: |
Miltenyi Biotec is picking up good VYBrations / New flow cytometer MACSQuant® VYB opens up novel avenues in cell analysis
Orlando, Florida ( na Originaltextservice ) - Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant® VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters. The MACSQuant VYB enables easy but sophisticated (...) |
| 2010-06-26: |
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 ( PRN/ots ) - Results from a 24 - week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level ( HbA1c ), in inadequately controlled type 2 diabetes patients who were (...) |
| 2006-12-04: |
Perceptronix's First ClearSign( TM ) Lung Cancer Testing Facility
Vancouver, Canada ( PRN/ots ) - Perceptronix Medical Inc. ( "Perceptronix" ) announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services' Victoria Drive Patient Service Centre in Vancouver. This facility will be the first centre to offer sputum induction for Perceptronix's (...) |
| 2004-10-08: |
Degussa fosters Professorship in Organic Synthetic Methods / Prof. Magnus Rüping follows call to Frankfurt on Main University
Dusseldorf ( na Originaltextservice ) - - Cross - reference: photo was sent via satellite and is available at http://www.presseportal.de/galerie.html Yesterday, Prof. Magnus Rüping ( 32 ) held his inaugural lecture in connection with the Professorship in Organic Synthetic Methods endowed on Johann Wolfgang Goethe (...) |
| 2010-06-24: |
Occlutech prevails in U.K. patent appeal by AGA Medical
Jena ( na Originaltextservice ) - In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this (...) |
| 2006-06-23: |
World's First Approval of New HIV Drug TMC114 Provides Potent New Treatment Option With FUZEON Making Goal of 'Undetectable' More Achievable for Patients Living With Drug Resistant HIV
Basel, Switzerland ( PRN/ots ) - The US approval of TMC114 ( darunavir ), a new boosted protease inhibitor ( PI ), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON ( enfuvirtide ) that can successfully combat the HIV virus in treatment resistant patients. Data (...) |
| 2009-10-05: |
Onglyza( R ) ( saxagliptin ) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( NYSE: BMY ) and AstraZeneca ( NYSE: AZN ) ( LSE: AZN ) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once - (...) |
| 2007-02-26: |
Fourth Phase III Study of Vandetanib ( ZACTIMA( TM ), ZD6474 ) in Patients With Advanced Lung Cancer
Alderley Park, England ( PRN/ots ) - - A Phase III international, parallel group, randomised, double - blind study of vandetanib in combination with pemetrexed for advanced non - small cell lung cancer ( NSCLC ) after failure of first line anti - cancer therapy AstraZeneca today announced that a (...) |
| 2011-02-23: |
Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event
LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 ( PRN/ots ) - - Sanofi Pasteur, the vaccines division of sanofi - aventis Group , today will participate in the first international bell - ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and (...) |
| 2004-11-16: |
Given the Choice, Women Prefer Endocrine Treatment With Zoladex( R ) ( goserelin ) to Chemotherapy for the Treatment of Early Breast Cancer
London, November 16 ( PRN/ots ) - New research published today in the European Journal of Cancer ( EJC ) ( 1 ) indicates that an overwhelming 78 per cent of healthy premenopausal women would prefer goserelin ( 'Zoladex ( TM )' ) therapy to chemotherapy if they were to develop oestrogen - receptor positive (...) |
| 2009-02-19: |
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
San Diego, California ( PRN/ots ) - A new analysis from the JUPITER study presented today at the International Stroke Conference ( ISC ) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary (...) |
| 2007-09-28: |
Eisai Announce Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
London ( PRN/ots ) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. ( Headquarters: Tokyo, President & CEO: Haruo Naito ) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by (...) |
| 2009-03-10: |
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced that DEFEND ( Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes ), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes (...) |
| 2010-05-19: |
The French Competition Authority Follows up Allegations of Anti - competitive Practices by Sanofi - Aventis to Exclude Fair Generic Competition for Plavix( R ) ( clopidogrel )
Utrecht, The Netherlands, May 19, 2010 ( PRN/ots ) - Teva Santé, one of France's leading generic medicines companies, has welcomed news that the French Competition Authority has agreed to its request to investigate alleged anti - competitive practices by Sanofi - Aventis aimed at preventing generic competition (...) |
| 2005-06-27: |
Tarceva Receives Positive Opinion in EU for the Treatment of Patients With Lung Cancer
Basel, Switzerland ( PRN/ots ) - Roche announced today that its innovative, oral cancer medicine Tarceva ( erlotinib ) has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of non - small cell lung cancer, the most common form (...) |
| 2007-08-22: |
Updated WHO Bird Flu ( H5N1 ) Management Guidance Reinforces Tamiflu as First Line Treatment
Basel, Switzerland ( PRN/ots ) - The World Health Organization ( WHO ) has reinforced that Tamiflu ( oseltamivir ) is the primary recommended antiviral of choice in managing patients infected with H5N1 in updated guidance published on the WHO website today. Experts believe that a human influenza pandemic is (...) |
| 2008-09-03: |
Resverlogix Board of Directors Update
Calgary, Canada ( PRN/ots ) - - Provides Shareholders With an Update on Strategic Review Activities On behalf of Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is (...) |
| 2010-06-07: |
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD - UPON - AVON, England, June 7, 2010 ( PRN/ots ) - - On World Heart Rhythm Week, Arrhythmia Alliance Launches 'Know Your Pulse' Campaign to Raise Awareness of the Importance of Pulse Checking to Keep Cardiac Conditions Under Control Arrhythmia Alliance, the Heart Rhythm (...) |
| 2007-07-03: |
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has assumed all marketing and distribution rights to BeneFIX( R ) Coagulation Factor IX ( Recombinant ) in Europe. This transfer of responsibility follows the planned June 30, 2007 conclusion of (...) |
| 2008-04-14: |
Botaneco Announces Launch of Second Generation Oleosome Product
Calgary, Canada ( PRN/ots ) - - Natural Hydresia( TM ) G2 Offers Enhanced Formulation Flexibility With a Globally Accepted Preservative System Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. ( TSX: SBS ), focused on the development and commercialization of oleosome technology in personal care, OTC and (...) |
| 2005-06-10: |
Degussa AG: World - Cup supersized / Specialties for the displays of tomorrow
Dusseldorf ( na Originaltextservice ) - There was bitter disappointment among countless football fans. In both the first and the second round of the FIFA world body’s lotterydraws they had failed to obtain soughtafter tickets for the 2006 football world championships in Germany. And hopes are slim for (...) |
| 2008-06-07: |
GRAZAX( R ) Demonstrates Significant Reductions on Asthma Symptoms in Children
Barcelona ( PRN/ots ) - - In Addition to Effects on Allergic Rhinitis ( Hayfever ), GRAZAX( R ) Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to 16 Years Old ALK - Abelló today presented successful results from a new clinical trial, GT - 12, designed to measure (...) |
| 2007-06-21: |
Phase II data show efficacy and tolerability of tapentadol in chronic pain treatment
Aachen ( na Originaltextservice ) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER ( extended release ) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism ( EULAR ), (...) |
| 2008-09-11: |
Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs
Ingelheim, Germany ( PRN/ots ) - - For Non - US Healthcare Media - Global QUEST Study Reveals Dogs With Congestive Heart Failure Have Significantly Improved Survival Outcomes With Vetmedin( R ) ( pimobendan ) Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended (...) |
| 2007-01-03: |
SemBioSys to Proceed With Abbreviated Regulatory Path for Plant - Produced Insulin After Meeting With the FDA
Calgary, Canada ( PRN/ots ) - - Canadian Biotechnology Company Shortens Clinical Timelines by Eliminating Duplicative Insulin Trials TSX symbol: SBS SemBioSys Genetics Inc. ( TSX: SBS ), a biotechnology company developing a broad pipeline of protein - based pharmaceuticals and non - pharmaceutical products, today provided an update (...) |
| 2008-04-18: |
Herceptin( R ) Helps Eradicate HER2 - Positive Breast Tumours When Given Before Surgery
BERLIN - European Breast Cancer Conference ( EBCC ), April 18 ( PRN/ots ) - - - For Non - UK and Non - US Media Only - Herceptin Offers Women With HER2 - Positive Breast Cancer the Best Chance of a Cure New data presented today as part of a late (...) |
| 2006-10-25: |
Boehringer Ingelheim: Unfounded Fear of Addiction Prevents Laxative Use
Berlin, Germany ( PRN/ots ) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of (...) |
| 2008-01-18: |
Novagali Pharma Announces FDA Clearance of IND for US Clinical Trial of Nova63035 in Patients With Diabetic Macular Edema
Evry, France ( PRN/ots ) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company announced today that the Company's Investigational New Drug Application ( IND ) to conduct a Phase I clinical trial of its Nova63035, an (...) |
| 2010-04-28: |
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL - C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 ( PRN/ots ) - New long - term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74 Prozent and 73.5 Prozent achieved NCEP* and EAS* low - density lipoprotein cholesterol ( LDL - (...) |
| 2009-09-28: |
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott Park, Illinois ( PRN/ots ) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long - term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending capacity to accelerate promising pipeline programs - Establishes Abbott's presence in the growing global (...) |
| 2007-11-15: |
EFIC - Grunenthal Grant 2007: The new generation of pain researchers
Aachen, Germany ( na Originaltextservice ) - - Cross reference: Picture is available at http://www.presseportal.de/galerie.htx?type=obs - Today the European Federation of Chapters of the International Association for the Study of Pain ( EFIC ) and the pharmaceutical company Grunenthal GmbH award five (...) |
| 2006-09-05: |
New Lipitor Data Published in The Lancet
New York ( PRN/ots ) - - Lipitor Reduces Risk of Major Cardiovascular Events Such as Heart Attacks in People With Heart Disease and With a Cluster of Other Major Cardiovascular Risk Factors, Often Referred to as Metabolic Syndrome, New Analysis Shows - Heart Disease Patients (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
